Jingze Biopharma (Hefei) Files for Hong Kong IPO With CICC, Guoyuan International as Sponsors
2026-07-06 05:52:50
Jingze Biopharma (Hefei) Co., Ltd. has submitted an application to list on the Hong Kong Stock Exchange, with China International Capital Corp (CICC) and Guoyuan International as joint sponsors, according to Jiemian News.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
South Korea's Korea Economic Association Calls for Basic Digital Asset Act to Expand STOsNext article：
三星晶圆代工6月据称实现月度盈利
